Gender and Its Impact on Risk Factors for Cardiovascular Disease

Principles of Gender-Specific Medicine

Volumn 1, Issue , 2004, Pages 193-214

  Bassuk, Shari S ^a   Manson, JoAnn E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1542314658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012440905-7/50286-3     Document Type: Chapter

References (234)

1. American Heart Association Heart Disease and Stroke Statistics-2003 Update 2002, American Heart Association.
2. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention. Circulation. 2000, 102:3137-3147.
3. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE The primary prevention of coronary heart disease in women. N Engl J Med. 1995, 332:1758-1766.
4. Wenger NK Gender differences in coronary risk and risk factors. Prevention of Myocardial Infarction 1996, 387-412. Oxford University Press, New York. J.E. Manson, P.M. Ridker, J.M. Gaziano, C.H. Hennekens (Eds.).
5. Manson JE, Spelsberg A Risk modification in the diabetic patient. Prevention of Myocardial Infarction 1996, 241-273. Oxford University Press, New York. J.E. Manson, P.M. Riker, J.M. Gaziano, C.H. Hennekens (Eds.).
6. Hennekens CH Risk factors for coronary heart disease in women. Cardiology Clinics. 1998, 16:1-8.
7. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994, 154:169-175.
8. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl. J Med. 1991, 324:1619-1625.
9. Beard CM, Kottke TE, Annergers JF, Ballard DJ The Rochester Coronary Heart Disease Project: Effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982. Mayo Clin Proc. 1989, 64:1471-1480.
10. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S The risk of mycardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985, 313:1511-1514.
11. Rosenberg L, Palmer JR, Shapiro S Decline in the risk of mycardial infarction among women who stop smoking. N Engl J Med. 1990, 322:213-217.
12. Dobson AJ, Alexander HM, Heller RF, Lloyd DM How soon after quiting smoking does risk of heart attack decline. J Clin Epidemiol. 1991, 44:1247-1253.
13. Hammond EC, Horn D Smoking and death rates: Report on forty-four months of follow-up of 187,783 men. II. Death rates by cause. JAMA. 1958, 166:1294-1308.
14. Hammond EC, Garfinkel L Coronary heart disease, stroke, and aortic aneurysm. Arch Environ Health. 1969, 19:167-182.
15. Rogot E, Murray JL Smoking and causes of death among U.S. veterans: 16 years of observation. Public Health Rep. 1980, 95:213-222.
16. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J. 1976, 2:1525-1536.
17. Jonas MA, Oates JA, Ockene JK, Hennekens CH Statement on smoking and cardiovascular disease for health care professionals. American Heart Association. Circulation 1992, 86:1664-1669.
18. Shinton R, Beevers G Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989, 298:789-794.
19. Kawachi I, Colditz GA, Stampfer M, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993, 269:232-236.
20. Rogers RL, Meyer JS, Judd BW, Mortel KF Abstention from cigarette smoking improves cerebral perfusion among elderly chronic smokers. JAMA 1985, 253:2970-2974.
21. Gill JS, Shipley MJ, Tsementzis SA, Hornby R, et al. Cigarette smoking. A risk factor for hemorrhagic and nonhemorrhagic stroke. Arch Intern Med. 1989, 149:2053-2057.
22. Ballantyne D, Devine BL, Fife R Interrelation of age, obesity, cigarette smoking, and blood pressure in hypertensive patients. BMJ. 1978, 1:880-881.
23. Kubota K, Yamaguchi T, Abe Y, et al. Effects of smoking on regional cerebral blood flow in neurologically normal subjects. Stroke. 1983, 14:720-724.
24. Evans A, Tolonen H, Hense HW, et al. Trends in coronary risk factors in the WHO MONICA project. Int J Epidemiol. 2001, 1(Suppl 30):S35-S40.
25. National Center for Health Statistics Health, United States, 1998 with Socioeconomic Status and Health Chartbook 1998.
26. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the U.S. adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995, 25:305-313.
27. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993, 153:186-208. National High Blood Pressure Education Program Working Group.
28. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol. 1976, 38:46-51.
29. Johnson JL, Heineman EF, Heiss G, et al. Cardiovascular disease risk factors and mortality among black women and white women aged 40-64 years in Evans County, Georgia. Am J Epidemiol. 1986, 123:209-220.
30. Sigurdsson JA, Bengstsson C, Lapidus L, et al. Morbidity and mortality in relation to blood pressure and antihypertensive treatment. A 12-year follow-up study of a population sample of Swedish women. Acta Med Scand. 1984, 215:313-322.
31. Fiebach NH, Hebert PR, Stampfer MJ, et al. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol. 1989, 130:646-654.
32. Stamler J, Stamler R, Neaton JD Blood pressure, systolic and diastolic, and cardiovascular risks. U.S. population data. Arch Intern Med. 1993, 153:598-615.
33. Thom TJ, Kannel WB, Silbershatz H, D'Agostino RB Cardiovascular diseases in the United States and prevention approaches. Hurt's The Heart 2001, 3-17. McGraw-Hill, New York. V. Fuster, R.W. Alexander, R.A. O'Rourke (Eds.).
34. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001, 345:1291-1297.
35. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999, 100:354-360.
36. Glynn RJ, Chae CU, Guralnik JM, et al. Pulse pressure and mortality in older people. Arch Intern Med. 2000, 160:2765-2772.
37. Sesso HD, Stampfer MJ, Rosner B, et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardio-vascular disease risk in men. Hypertension. 2000, 36:801-807.
38. Glynn RJ, L'Italien GJ, Sesso HD, et al. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension. 2002, 39:105-110.
39. Martins D, Nelson K, Pan D, et al. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: Data from NHANES III. J Gend Specif Med. 2001, 4:10-13.
40. Martins D, Nelson K, Pan D, et al. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: Data from NHANES III. J Gend Specif Med. 2001, 4:20.
41. Prevention of stroke by antihy-pertensive drug treatment inolder persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991, 265:3255-3264. SHEP Cooperative Research Group.
42. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764.
43. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998, 16:1823-1829.
44. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials. Lancet. 2000, 355:865-872.
45. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985, 1:1349-1354.
46. Coope J, Warrender TS Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ (Clin Res Ed.) 1986, 293:1145-1151.
47. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991, 338:1281-1285.
48. Medical Research Council Working Party MRC trial of treatment of mild hypertension: Principal results. BMJ (Clin Res Ed) 1985, 291:97-104.
49. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979, 242:2562-2571. Hypertension Detection and Follow-up Program Cooperative Group.
50. Medical Research Council Working Party Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ. 1992, 304:405-412.
51. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997, 126:761-767.
52. American College of Obstetricians and Gynecologists Hypertension in pregnancy. ACOG Technical Bulletin. 1996, 21:1-8.
53. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000, 183:S1-S22. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.
54. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Twenty-year dynamics of serum cholesterol levels in the middle-aged population of eastern Finland. Ann Intern Med. 1996, 125:713-722.
55. Johnson CL, Rifkind BM, Sempos CT, et al. Decling serum total cholesterol levels among U.S. adults. The National Health and Nutrition Examination Surveys. JAMA 1993, 269:3002-3008.
56. Welty FK Who should receive hormone replacement therapy?. J Thromb Thrombolysis. 1996, 3:13-21.
57. Campos H, McNamara JR, Wilson PW, et al. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988, 67:30-35.
58. Steveson JC, Crook D, Godsland IF Influence of age and meno-pause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993, 98:83-90.
59. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990, 81:1721-1733.
60. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Ann Epidemiol. 1992, 2:161-176.
61. Walsh JM, Grady D. Tretment of hyperlipidemia in women. JAMA 1995, 274:1152-1158.
62. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995, 274:539-544.
63. Zimetbaum P, Frishman WH, Ooi WL, et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study. Arterioscler Thromb. 1992, 12:416-423.
64. Kannel WB, Wilson PW Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995, 155:57-61.
65. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989, 321:641-646.
66. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med. 1997, 157:961-968.
67. Castelli WP The triglyceride issue: A view from Framingham. Am Heart J. 1986, 112:432-437.
68. Austin MA, Hokanson JE, Edwards KL Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998, 81:7B-12B.
69. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001, 104:1108-1113.
70. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001, 153:490-499.
71. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000, 102:1082-1085.
72. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simwastatin Survival Study (4S). Circulation. 1997, 96:4211-4218.
73. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335:1001-1009.
74. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardio-vascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998, 32:140-146.
75. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998, 339:1349-1357. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
76. MRC/BHF Heart Protection Study of cholesterol lowering with simvastain in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002, 360:7-22. Heart Protection Study Collaborative Group.
77. LaRosa JC, He J, Vupputuri S. Effect of station on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999, 282:2340-2346.
78. Schrott HG, Bittner V, Vittinghoff E, et al. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/progestin Replacement Study (HERS). The HERS Research Group. JAMA. 1997, 277:1281-1286.
79. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995, 333:1301-1307.
80. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998, 279:1615-1622.
81. Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997, 96:2468-2482.
82. Flegal KM, Carroll MD, Ogden CL, Johnson CL Prevalence and trends in obesity among US adults. JAMA 2002, 288:1723-1727.
83. Eckel RH, Krauss RM American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998, 97:2099-2100.
84. Rexrode KM, Manson JE, Henekens CH Obesity and cardiovascular disease. Curr Opin Cardiol 1996, 11:490-495.
85. Duncan BB, Schmidt MI, Chambless LE, et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC study. Atherosclerosis Risk in Communities. Obes Res 2000, 8:279-286.
86. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
87. Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998, 128:81-88.
88. Ashton WD, Nanchahal K, Wood DA Body mass index and metabolic risk factors for coronary heart disease in women. Eur Heart J 2001, 22:46-55.
89. Garrison RJ, Kannel WB A new approach for estimating healthy body weights. Int J Obes Relat Metab Disord 1993, 17:417-423.
90. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995, 273:461-465.
91. Hubert HB, Feinleib M, McNamara PM, Castelli WP Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968-977.
92. Carey DG Abdominal obesity. Curr Opin Lipidol 1998, 9:35-40.
93. Folsom AR, Prineas RJ, Kaye SA, Munger RG Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke 1990, 21:701-706.
94. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997, 145:614-619.
95. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998, 280:1843-1848.
96. Kaplan NM The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989, 149:1514-1520.
97. Rexrode KM, Buring JE, Manson JE Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001, 25:1047-1056.
98. Haffner SM, Katz MS, Dunn JF Increased upper body and overall adiposity is associated with decreased sex hormone binding globulin in post-menopausal women. Int J Obes 1991, 15:471-478.
99. Stefanick M Exercise and weight loss. Clinical Trials in Cardiovascular Disease 1999, 375-391. WB Saunders, Philadelphia. C.H. Hennekens, J.E. Buring, J.E. Manson, P.M. Ridker (Eds.).
100. Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997, 277:1539-1545.
101. Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002, 162:2557-2562.
102. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195-1200.
103. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997, 277:642-645.
104. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.
105. Diabetes Facts and Figures 1999, American Diabetes Association.
106. King H, Aubert RE, Herman WH Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
107. Gu K, Cowie CC, Harris MI Diabetes and decline in heart disease mortality in U.S. adults. JAMA 1999, 281:1291-1297.
108. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001, 161:1717-1723.
109. Cho E, Rimm EB, Stampfer M, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in men. J Am Coll Cardiol 2002, 40:954-960.
110. Siegel RD, Cupples A, Schaefer EJ, Wilson PW Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism 1996, 45:1267-1272.
111. Cowie CC, Harris MI Physical and metabolic characteristics of persons with diabetes. Diabetes in America 1995, 1468:117-164. (95), National Institutes of Health. 2nd Edition.
112. Ruderman NB, Haudenschild C Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984, 26:373-412.
113. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 2002, 25:55-60.
114. Steinberg HO, Paradisi G, Cronin J, et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 2000, 101:2040-2046.
115. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151:1141-1147.
116. Aspirin therapy in diabetes. Diabetes Care 1997, 20:1772-1773. American Diabetes Association.
117. U.S.Department of Health and Human Services Physical Activity and Health: A Report of the Surgeon General 1996, U.S. Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA.
118. Schoenborn CA, Barnes PM Leisure-time Physical Activity among Adults: United States, 1997-98. Advance Data from Vital and Health Statistics; No. 325 2002, National Center for Health Statistics, Hyattsville, MD.
119. Berlin JA, Colditz GA A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990, 132:612-628.
120. Lee IM, Rexrode KM, Cook NR, et al. Physical activity and coronary heart disease in women: Is 'no pain, no gain' passe?. JAMA 2001, 285:1447-1454.
121. Sesso HD, Paffenbarger RS, Ha T, Lee IM Physical activity and cardiovascular disease risk in middle-aged and older women. Am J Epidemiol 1999, 150:408-416.
122. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002, 347:716-725.
123. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999, 341:650-658.
124. Hu FB, Stampfer MJ, Colditz GA, et al. Physical activity and risk of stroke in women. JAMA 2000, 283:2961-2967.
125. Bassuk SS, Manson JE Physical activity and the prevention of cardiovascular disease. Curr Atheroscler Rep 2003, 5:299-307.
126. Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: A randomized controlled trial. JAMA 2003, 289:323-330.
127. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
128. Stadel BV Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981, 305:672-677.
129. Chasan-Taber L, Stampfer MJ Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998, 128:467-477.
130. Rosenberg L, Palmer JR, Rao RS, Shapiro S Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001, 161:1065-1070.
131. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. Lancet 1997, 349:1202-1209. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Group.
132. Stampfer MJ, Willett WC, Colditz GA, et al. Past use of oral contraceptives and cardiovascular disease: A meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 1990, 163:285-291.
133. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001, 345:1787-1793.
134. Lewis MA, Heinemann LA, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997, 56:129-140.
135. Lidegaard O Oral contraception and risk of a cerebral thromboembolic attack: Results of a case-control study. BMJ 1993, 306:956-963.
136. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995, 310:830-833.
137. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. Lancet 1996, 348:498-505. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Group.
138. Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996, 335:8-15.
139. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996, 348:505-510. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Group.
140. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995, 346:1575-1582. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Group.
141. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995, 346:1582-1588. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Group.
142. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996, 312:83-88.
143. Farmer RD, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997, 349:83-88.
144. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997, 97:233-238.
145. Barrett-Connor E, Grady D Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998, 19:55-72.
146. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000, 133:933-941.
147. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
148. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208. Writting Group for the PEPI Trial.
149. Binder EF, Williams DB, Schechtman KB, et al. Effects of hormone replacement therapy on serum lipids in elderly women. A randomized, placebo-controlled trial. Ann Intern Med 2001, 134:754-760.
150. Chae CU, Manson JE Postmenopausal hormone replacement therapy. Clinical Trials in Cadiovascular Disease: A Companion to Brauwald's Heart Disease 1999, 399-414. WB Saunders, Philadelphia. C.H. Hennekens, J.E. Buring, J.E. Manson, P.M. Ridker (Eds.).
151. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999, 100:717-722.
152. Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
153. Manson JE, Martin KA Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 2001, 345:34-40.
154. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002, 288:49-57.
155. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522-529.
156. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT atherosclerosis study. BJOG 2002, 109:1056-1062.
157. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243-1249.
158. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 2002, 288:2432-2440.
159. Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet 2002, 360:2001-2008. ESPRIT team.
160. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000, 283:1845-1852.
161. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002, 346:967-974.
162. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001, 285:906-913.
163. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
164. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003, 289:2673-2684.
165. Hemminki E, McPherson K Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. BMJ 1997, 315:149-153.
166. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators.
167. Miller J, Chan BK, Nelson HD Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 136:680-690.
168. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348:983-987.
169. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000, 132:689-696.
170. Vincent A, Fitzpatrick LA Soy isoflavones: Are they useful in menopause?. Mayo Clin Proc 2000, 75:1174-1184.
171. Barrett-Connor E Raloxifene: Risks and benefits. Ann NY Acad Sci 2001, 949:295-303.
172. Anderson JW, Johnstone BM, Cook-Newell M Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995, 333:276-282.
173. Clarkson TB, Anthony MS Phytoestrogens and coronary heart disease. Baillieres Clin Endocrinol Metab 1998, 12:589-604.
174. Wangen KE, Duncan AM, Xu X, Kurzer MS Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr 2001, 73:225-231.
175. Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: A placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 2001, 86:3053-3060.
176. Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999, 84:895-898.
177. Washburn S, Burke GL, Morgan T, Anthony M Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999, 6:7-13.
178. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445-1451.
179. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2000, 85:214-218.
180. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001, 21:1512-1519.
181. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287:847-857.
182. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001, 88:392-395.
183. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
184. Witztum JL The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
185. Verlangieri AJ, Bush MJ Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr 1992, 11:131-138.
186. Steiner M Influence of vitamin E on platelet function in humans. J Am Coll Nutr 1991, 10:466-473.
187. Stamler J, Ruth KJ, Liu K, Shekelle RB Dietary antioxidants and blood pressure in the Western Electric Study [Abstract]. 34th Annual Conference on Cardiovascular Epidemiology and Prevention 1993.
188. Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996, 93:1107-1113.
189. Keaney JF, Gaziano JM, Xu A, et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci U.S.A. 1993, 90:11880-11884.
190. Albert CM, Manson JE Aspirin, antioxidants, and alcohol. Coronary Artery Disease in Women: What All Physicians Need to Know 1999, 236-263. American College of Physicians, Philadelphia. P. Charney (Ed.).
191. Stampfer M, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993, 328:1444-1449.
192. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993, 328:1450-1456.
193. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996, 334:1156-1162.
194. Knekt P, Reunanen A, Jarvinen R, et al. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994, 139:1180-1189.
195. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
196. Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998, 158:668-675.
197. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico).
198. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154-160.
199. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
200. de Gaetano G Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001, 357:89-95.
201. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33. Heart Protection Study Collaborative Group.
202. Pruthi S, Allison TG, Hensrud DD Vitamin E supplementation in the prevention of coronary heart disease. Mayo Clin Proc 2001, 76:1131-1136.
203. Rosenberg L, Slone D, Shapiro S, et al. Alcoholic beverages and myocardial infarction in young women. Am J Public Health 1981, 71:82-85.
204. Scragg R, Stewart A, Jackson R, Beaglehole R Alcohol and exercise in myocardial infarction and sudden coronary death in men and women. Am J Epidemiol 1987, 126:77-85.
205. Gaziano JM, Hennekens CH, Godfried SL, et al. Type of alcoholic beverage and risk of myocardial infarction. Am J Cardiol 1999, 83:52-57.
206. Klatsky AL, Friedman GD, Siegelaub AB Alcohol consumption before myocardial infarction. Results from the Kaiser-Permanente epidemiologic study of myocardial infarction. Ann Intern Med 1974, 81:294-301.
207. Gordon T, Kannel WB Drinking habits and cardiovascular disease: The Framingham Study. Am Heart J 1983, 105:667-673.
208. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988, 319:267-273.
209. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med 1995, 332:1245-1250.
210. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997, 337:1705-1714.
211. Rehm JT, Bondy SJ, Sempos CT, Vuong CV Alcohol consumption and coronary heart disease morbidity and mortality. Am J Epidemiol 1997, 146:495-501.
212. Klatsky AL, Armstrong MA, Friedman GD Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. Am J Cardiol 1997, 80:416-420.
213. Sesso HD, Gaziano JM Alcohol intake and cardiovascular morbidity and mortality. Curr Opin Nephrol Hypertens 1999, 8:353-357.
214. Landolfi R, Steiner M Ethanol raises prostacyclin in vivo and in vitro. Blood 1984, 64:679-682.
215. Ridker PM, Vaughan DE, Stampfer MJ, et al. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA 1994, 272:929-933.
216. Laug WE Ethyl alcohol enhances plasminogen activator secretion by endothelial cells. JAMA 1983, 250:772-776.
217. MacMahon S Alcohol consumption and hypertension. Hypertension 1987, 9:111-121.
218. Longnecker MP Alcoholic beverage consumption in relation to risk of breast cancer: Meta-analysis and review. Cancer Causes Control 1994, 5:73-82.
219. Norton R, Batey R, Dwyer T, MacMahon S Alcohol consumption and the risk of alcohol related cirrhosis in women. BMJ (Clin Res Ed) 1987, 295:80-82.
220. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995, 274:149-154.
221. Libby P, Ridker PM, Maseri A Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
222. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
223. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
224. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA 2002, 288:980-987.
225. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
226. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
227. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003, 289:1799-1804.
228. Bazzano LA, He J, Muntner P, et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003, 138:891-897.
229. Albert MA, Danielson E, Rifai N, Ridker PM Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286:64-70.
230. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
231. Ridker PM, Rifai N, Lowenthal SP Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001, 103:1191-1193.
232. Kinlay S, Timms T, Clark M, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002, 89:1205-1207.
233. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839-844.
234. Ridker PM Rosuvastatin in the primary prevention of cardiovascular disease among patient with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER Trial. Circulation 2003, 108:2292-2297. on behalf of the, JUPITER Study GroupJUPITER Study Group.